a Institute for Medical Microbiology and Virology, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany b Eijkman-Winkler Institute for Medical Microbiology, Utrecht University, Utrecht, The Netherlands
Sir,
During the past two decades Gram-positive bacteria, predominantly staphylococci and streptococci, have re-emerged as important pathogens. Staphylococci, in particular, have demonstrated a remarkable propensity for acquiring mechanisms of resistance to every new antimicrobial to become available and for spreading among patients, institutions and communities. More recently, there have also been increasing concerns about ß-lactam resistance in Streptococcus pneumoniae and other streptococci. Clearly, there is a pressing need to identify novel compounds that can be used as therapy for patients with infections caused by these organisms.1
Quinupristin/dalfopristin, a combination of two streptogramins, is one such agent. It has been shown to have excellent activity in vitro against a broad range of staphylococci and streptococci, including strains that exhibit multidrug resistance.2 Resistance to streptogramins can develop through one of several mechanismsalteration of the target site (the most common mechanism), active transport or efflux mediated by an ATP-binding protein and enzyme modification.3 The aims of the present study were to determine the antibiotic susceptibilities of strains of Staphylococcus aureus and Streptococcus spp. exhibiting intermediate susceptibility or resistance to quinupristin/dalfopristin and to investigate the clonal relatedness of these strains.
The bacteria studied were identified from among a total of 2393 strains of S. aureus
(574
of which were resistant to methicillin), 963 of S. pneumoniae and 486 of other Streptococcus spp. isolated in 24 university hospitals participating in the European
SENTRY
antimicrobial surveillance programme between April 1997 and February 1999. MICs of
quinupristin/dalfopristin for the isolates were determined by a microbroth dilution method
recommended
by the NCCLS.4 The susceptibilities of strains for which the
MICs of quinupristin/dalfopristin were 2 mg/L to several antibiotics were then determined
by
the
same microbroth dilution method. The antibiotics were as follows: penicillin, oxacillin,
ciprofloxacin,
gentamicin, erythromycin, clindamycin, teicoplanin, vancomycin and the novel oxazolidinone,
linezolid.
In addition, the S. aureus strains were typed by a PFGE method described previously.5
Of the 3842 non-replicate strains submitted, 21 (0.9%) S. aureus isolates, one (0.1%) S. pneumoniae isolate and six (1.2%) other Streptococcus spp. isolates (comprising one strain each of Streptococcus mitis, Streptococcus oralis, Streptococcus bovis, Streptococcus porcinus, Streptococcus intermedius and Streptococcus sanguis) exhibited intermediate susceptibility or resistance to quinupristin/dalfopristin. Of the 21 S. aureus isolates, 18 were methicillin-resistant (MRSA) and three were methicillin-susceptible (MSSA); therefore 3.1% of MRSA isolates and 0.2% of MSSA isolates were non-susceptible to quinupristin/dalfopristin.
Most (16) of the 21 S. aureus strains that were resistant to quinupristin/dalfopristin were referred from three hospitals in France, one of which contributed 14 strains. The remainder came from hospitals in Spain (three strains), Austria (one) and the UK (one). The single quinupristin/dalfopristin-resistant S. pneumoniae isolate was isolated in Germany and the six Streptococcus spp. isolates were from France (two strains), Austria (one), Italy (one), The Netherlands (one) and Turkey (one). Twenty-three (82%) of the 28 isolates were recovered from patients with bacteraemias, the remaining strains being isolated from patients with wound infections (three strains) or nosocomial pneumonias (two).
The susceptibilities of the 28 strains are summarized in the Table. All 21 quinupristin/dalfopristin-resistant S. aureus isolates expressed the MLSB resistance phenotype and were resistant to penicillin and ciprofloxacin. The 18 MRSA isolates were also resistant to gentamicin (with 16 exhibiting high-level resistance) and five exhibited intermediate susceptibility to vancomycin (MICs 4 mg/L). The single quinupristin/dalfopristin-resistant S. pneumoniae isolate was susceptible to penicillin, vancomycin and clindamycin, but resistant to erythromycin; this strain therefore expressed the so-called M phenotype. Three of the six quinupristin/dalfopristin-resistant Streptococcus spp. isolates exhibited intermediate susceptibility or resistance to penicillin and all six expressed the MLSB resistance phenotype and exhibited reduced susceptibility to ciprofloxacin. All 28 strains were susceptible to linezolid (MICs 0.121 mg/L) (data not shown), an observation which suggests that it would have a role in the treatment of patients with infections caused by multidrug-resistant Gram-positive bacteria, including those resistant to quinupristin/dalfopristin.
|
The results of this study indicate that the numbers of S. aureus and Streptococcus spp. (including S. pneumoniae) strains resistant to quinupristin/dalfopristin are currently very low in Europe. The majority of such organisms were isolated in France and this may have been the result of nosocomial spread of MRSA in one hospital. (Indeed, more than 95% of the MRSA strains isolated in that hospital exhibited resistance to multiple drugs, including quinupristin/dalfopristin.) Our results are in accord with those of a multicentre study carried out in 200 laboratories in the USA,1,2 in which 99% of S. aureus isolates, 98% of S. pneumoniae isolates and 97% of Streptococcus spp. isolates were shown to be susceptible to quinupristin/dalfopristin. Furthermore, a recent German surveillance study found no quinupristin/dalfopristin-resistant strains among 1359 staphylococci isolated from blood cultures.6
As streptogramin compounds have been used in France for more than 25 years, it is not
entirely
surprising that the incidence of resistance to quinupristin/dalfopristin among isolates from that
country
was higher than those among isolates from other countries. However, during a national survey in
1995,
when 895 MRSA strains from 96 French non-university hospitals were studied, the MICs of
quinupristin/dalfopristin for only 1.5% of these strains were 4 mg/L.7 Moreover, of the 37,775 S. aureus strains isolated from clinical
specimens at
Pitié-Salpêtrière Hospital between 1973 and 1996,
quinupristin/dalfopristin
resistance was found in
1% of MSSA isolates and
5% of MRSA isolates.8
In conclusion, resistance to quinupristin/dalfopristin among staphylococci and streptococci isolated in European university hospitals is still rare. None the less, as most of the resistant isolates were recovered from patients with bacteraemias and exhibited resistance to multiple other antibiotics, problems with treatment may arise in the future. A particular concern is that resistance to quinupristin/dalfopristin will increase as the drug is used more extensively. It is reassuring therefore that linezolid is currently active against all isolates resistant to quinupristin/dalfopristin. Finally, as most of the quinupristin/dalfopristin-resistant strains investigated in this study were isolated in 1998, ongoing surveillance to identify trends in resistance to this agent among Gram-positive bacteria must be a priority.
Acknowledgments
We thank Marita Hautvast, Miriam Klootwijk, Carlijn Kusters and Stefan de Vaal for their expert technical assistance. This study was funded by Bristol-Myers Squibb Parmaceuticals via the SENTRY Antimicrobial Surveillance Program.
Notes
* Correspondence address. Institute for Medical Microbiology and
Virology,
Heinrich-Heine University Düsseldorf, Universitätsstraße 1, Geb. 22.21,
D-40225
Düsseldorf, Germany. Tel: +49-2132-72040; Fax: +49-2132-72040; E-mail: schmitfj{at}uni-duesseldorf.de
References
1 . Jones, R. N., Low, D. E. & Pfaller, M. A. (1999). Epidemiologic trends in nosocomial and community-aquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagnostic Microbiology and Infectious Disease 33, 10112.[ISI][Medline]
2 . Jones, R. N., Ballow, C. H., Biedenbach, D. J., Deinhart, J. A. & Schentag, J. J. (1998). Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. Diagnostic Microbiology and Infectious Disease 31, 43751.[ISI][Medline]
3
.
Thal, L. A. & Zervos, M. J. (1999).
Occurrence and epidemiology of resistance to virginiamycin and streptogramins. Journal of Antimicrobial Chemotherapy 43, 1716.
4 . National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow AerobicallyFourth Edition: Approved Standard M7-A4. NCCLS, Wayne, PA.
5 . Schmitz, F. J., Steiert, M., Tichy, H. V., Hofmann, B., Verhoef, J., Heinz, H. P. et al. (1998). Typing of methicillin-resistant Staphylococcus aureus isolates from Düsseldorf by six genotypic methods. Journal of Medical Microbiology 47,341 51.[Abstract]
6 . von Eiff, C., Reinert, R. R. & Peters, G. for the Study Group. (1999). Prevalence of antibiotic resistance in staphylococci from patients with bacteremia in German tertiary care hospitals. In Abstracts of the Ninth European Congress of Clinical Microbiology and Infectious Diseases, Berlin, 1999. Abstract 881. Clinical Microbiology and Infection 5, Suppl. 3, 321.
7 . Gazagne, L., Gueudet, P., Lecaillon, E., Le Coustumier, A. L. & Bismuth, R. (1998). In vitro activity of streptogramins against 45 methicillin-resistant Staphylococcus aureus with decreased susceptibility to dalfopristin. In Program and Abstracts of the Fourth International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, Barcelona, 1998. Poster 3.23.
8 . Bismuth, R., Nguyen, J., Truffort, C., Cambau, E., Lemaitre, N., Robert, J. et al. (1998). Macrolides, lincosamides and streptogramins resistance in Staphylococcus aureus: a 24 year survey in a large teaching hospital. In Program and Abstracts of the Fourth International Conference on the Macrolides, Azalides, Streptogramins and Ketolides, Barcelona, 1998. Poster 3.22.